$CRNX
Crinetics Pharmaceuticals, Inc.

2022 Q4 Form 10-Q Financial Statement

#000095017022024736 Filed on November 14, 2022

View on sec.gov

Income Statement

Concept 2022 Q4 2022 Q3 2021 Q3
Revenue $709.0K $458.0K $0.00
YoY Change -34.23%
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin $11.27M $11.93M $6.227M
YoY Change 53.14% 91.5% 31.09%
% of Gross Profit
Research & Development $36.99M $31.99M $21.58M
YoY Change 50.35% 48.23% 57.53%
% of Gross Profit
Depreciation & Amortization $280.0K $248.0K $233.0K
YoY Change 19.15% 6.44% -2.92%
% of Gross Profit
Operating Expenses $48.27M $43.91M $27.81M
YoY Change 50.99% 57.92% 50.71%
Operating Profit -$43.45M -$27.81M
YoY Change 56.27%
Interest Expense $30.57M $1.463M -$23.00K
YoY Change 41780.82% -6460.87% -119.17%
% of Operating Profit
Other Income/Expense, Net -$28.01M $1.529M -$21.00K
YoY Change -133471.43% -7380.95% -116.03%
Pretax Income -$44.99M -$41.93M -$27.85M
YoY Change 46.1% 50.53% 52.03%
Income Tax
% Of Pretax Income
Net Earnings -$44.99M -$41.93M -$27.85M
YoY Change 46.1% 50.53% 52.03%
Net Earnings / Revenue -6345.7% -9153.93%
Basic Earnings Per Share -$0.78 -$0.73
Diluted Earnings Per Share -$0.84 -$0.78 -$727.0K
COMMON SHARES
Basic Shares Outstanding 53.81M 53.75M 38.31M
Diluted Shares Outstanding 53.77M 38.31M

Balance Sheet

Concept 2022 Q4 2022 Q3 2021 Q3
SHORT-TERM ASSETS
Cash & Short-Term Investments $311.3M $368.4M $193.3M
YoY Change -6.71% 90.54% 3.49%
Cash & Equivalents $32.67M $30.91M $161.5M
Short-Term Investments $278.6M $337.5M $31.79M
Other Short-Term Assets $2.535M $1.652M $959.0K
YoY Change 177.96% 72.26% 45.52%
Inventory
Prepaid Expenses
Receivables
Other Receivables $135.0K
Total Short-Term Assets $345.2M $378.3M $204.0M
YoY Change 0.13% 85.48% 5.09%
LONG-TERM ASSETS
Property, Plant & Equipment $3.500M $3.564M $2.903M
YoY Change 23.89% 22.77% -14.34%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments $0.00 $0.00
YoY Change -100.0%
Other Assets $37.00K $1.399M $500.0K
YoY Change 179.8% 0.0%
Total Long-Term Assets $6.992M $6.557M $5.386M
YoY Change 11.07% 21.74% -13.37%
TOTAL ASSETS
Total Short-Term Assets $345.2M $378.3M $204.0M
Total Long-Term Assets $6.992M $6.557M $5.386M
Total Assets $352.2M $384.9M $209.4M
YoY Change 0.33% 83.84% 4.51%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $6.883M $5.877M $6.153M
YoY Change 101.14% -4.49% 30.91%
Accrued Expenses $18.60M $16.36M $6.287M
YoY Change 147.11% 160.2% 53.34%
Deferred Revenue
YoY Change
Short-Term Debt $0.00 $0.00 $0.00
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities $27.72M $24.56M $12.44M
YoY Change 73.32% 97.4% 40.84%
LONG-TERM LIABILITIES
Long-Term Debt $0.00 $0.00 $0.00
YoY Change
Other Long-Term Liabilities $8.125M $8.952M $3.329M
YoY Change 164.14% 168.91% -22.58%
Total Long-Term Liabilities $8.125M $8.952M $3.329M
YoY Change 164.14% 168.91% -22.58%
TOTAL LIABILITIES
Total Short-Term Liabilities $27.72M $24.56M $12.44M
Total Long-Term Liabilities $8.125M $8.952M $3.329M
Total Liabilities $35.85M $33.51M $15.77M
YoY Change 87.97% 112.49% 20.42%
SHAREHOLDERS EQUITY
Retained Earnings -$439.2M -$394.2M -$244.5M
YoY Change 59.56% 61.23% 67.47%
Common Stock $0.00
YoY Change
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity $316.3M $351.4M $193.6M
YoY Change
Total Liabilities & Shareholders Equity $352.2M $384.9M $209.4M
YoY Change 0.33% 83.84% 4.51%

Cashflow Statement

Concept 2022 Q4 2022 Q3 2021 Q3
OPERATING ACTIVITIES
Net Income -$44.99M -$41.93M -$27.85M
YoY Change 46.1% 50.53% 52.03%
Depreciation, Depletion And Amortization $280.0K $248.0K $233.0K
YoY Change 19.15% 6.44% -2.92%
Cash From Operating Activities -$35.21M -$38.48M -$25.67M
YoY Change 53.75% 49.88% 42.63%
INVESTING ACTIVITIES
Capital Expenditures $274.0K -$682.0K -$140.0K
YoY Change -1622.22% 387.14% 40.0%
Acquisitions
YoY Change
Other Investing Activities $37.13M $7.504M -$6.885M
YoY Change -136.48% -208.99% -72.16%
Cash From Investing Activities $36.85M $6.822M -$7.025M
YoY Change -136.2% -197.11% -71.71%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities 115.0K 1.076M 15.46M
YoY Change -99.93% -93.04% -9764.38%
NET CHANGE
Cash From Operating Activities -35.21M -38.48M -25.67M
Cash From Investing Activities 36.85M 6.822M -7.025M
Cash From Financing Activities 115.0K 1.076M 15.46M
Net Change In Cash 1.761M -30.58M -17.24M
YoY Change -95.5% 77.44% -59.91%
FREE CASH FLOW
Cash From Operating Activities -$35.21M -$38.48M -$25.67M
Capital Expenditures $274.0K -$682.0K -$140.0K
Free Cash Flow -$35.48M -$37.80M -$25.53M
YoY Change 55.07% 48.03% 42.64%

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
CY2022Q3 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
dei Amendment Flag
AmendmentFlag
false
dei Entity Central Index Key
EntityCentralIndexKey
0001658247
CY2022Q3 us-gaap Type Of Revenue Extensible List
TypeOfRevenueExtensibleList
http://fasb.org/us-gaap/2022#GrantMember
CY2021Q4 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2021Q3 us-gaap Type Of Revenue Extensible List
TypeOfRevenueExtensibleList
http://fasb.org/us-gaap/2022#GrantMember
dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--12-31
us-gaap Type Of Revenue Extensible List
TypeOfRevenueExtensibleList
http://fasb.org/us-gaap/2022#GrantMember
us-gaap Type Of Revenue Extensible List
TypeOfRevenueExtensibleList
http://fasb.org/us-gaap/2022#GrantMember
dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
Q3
dei Document Type
DocumentType
10-Q
dei Document Quarterly Report
DocumentQuarterlyReport
true
dei Document Period End Date
DocumentPeriodEndDate
2022-09-30
dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2022
dei Document Transition Report
DocumentTransitionReport
false
dei Entity File Number
EntityFileNumber
001-38583
dei Entity Registrant Name
EntityRegistrantName
Crinetics Pharmaceuticals, Inc.
dei Entity Incorporation State Country Code
EntityIncorporationStateCountryCode
DE
dei Entity Tax Identification Number
EntityTaxIdentificationNumber
26-3744114
dei Entity Address Address Line1
EntityAddressAddressLine1
10222 Barnes Canyon Road
dei Entity Address Address Line2
EntityAddressAddressLine2
Bldg. #2
dei Entity Address City Or Town
EntityAddressCityOrTown
San Diego
dei Entity Address State Or Province
EntityAddressStateOrProvince
CA
dei Entity Address Postal Zip Code
EntityAddressPostalZipCode
92121
dei City Area Code
CityAreaCode
858
dei Local Phone Number
LocalPhoneNumber
450-6464
dei Security12b Title
Security12bTitle
Common Stock, par value $0.001 per share
dei Trading Symbol
TradingSymbol
CRNX
dei Security Exchange Name
SecurityExchangeName
NASDAQ
dei Entity Current Reporting Status
EntityCurrentReportingStatus
Yes
dei Entity Interactive Data Current
EntityInteractiveDataCurrent
Yes
dei Entity Filer Category
EntityFilerCategory
Non-accelerated Filer
dei Entity Small Business
EntitySmallBusiness
true
dei Entity Emerging Growth Company
EntityEmergingGrowthCompany
true
dei Entity Ex Transition Period
EntityExTransitionPeriod
true
dei Entity Shell Company
EntityShellCompany
false
CY2022Q4 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
53810476
CY2022Q3 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
30912000
CY2021Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
200695000
CY2022Q3 us-gaap Short Term Investments
ShortTermInvestments
337450000
CY2021Q4 us-gaap Short Term Investments
ShortTermInvestments
133012000
CY2022Q3 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
9961000
CY2021Q4 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
11013000
CY2022Q3 us-gaap Assets Current
AssetsCurrent
378323000
CY2021Q4 us-gaap Assets Current
AssetsCurrent
344720000
CY2022Q3 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
3564000
CY2021Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
2825000
CY2022Q3 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
1594000
CY2021Q4 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
1892000
CY2022Q3 us-gaap Derivative Assets
DerivativeAssets
99000
CY2021Q4 us-gaap Derivative Assets
DerivativeAssets
68000
CY2022Q3 crnx Investment In Radionetics
InvestmentInRadionetics
0
CY2021Q4 crnx Investment In Radionetics
InvestmentInRadionetics
1010000
CY2022Q3 us-gaap Restricted Cash Noncurrent
RestrictedCashNoncurrent
1300000
CY2021Q4 us-gaap Restricted Cash Noncurrent
RestrictedCashNoncurrent
500000
CY2022Q3 us-gaap Assets
Assets
384880000
CY2021Q4 us-gaap Assets
Assets
351015000
CY2022Q3 us-gaap Accounts Payable And Accrued Liabilities Current
AccountsPayableAndAccruedLiabilitiesCurrent
13495000
CY2021Q4 us-gaap Accounts Payable And Accrued Liabilities Current
AccountsPayableAndAccruedLiabilitiesCurrent
8468000
CY2022Q3 crnx Accrued Compensation And Related Expense
AccruedCompensationAndRelatedExpense
7719000
CY2021Q4 crnx Accrued Compensation And Related Expense
AccruedCompensationAndRelatedExpense
6588000
CY2022Q3 us-gaap Deferred Revenue
DeferredRevenue
2320000
CY2021Q4 us-gaap Deferred Revenue
DeferredRevenue
0
CY2022Q3 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
1022000
CY2021Q4 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
939000
CY2022Q3 us-gaap Liabilities Current
LiabilitiesCurrent
24556000
CY2021Q4 us-gaap Liabilities Current
LiabilitiesCurrent
15995000
CY2022Q3 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
2300000
CY2021Q4 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
3074000
CY2022Q3 us-gaap Deferred Revenue Noncurrent
DeferredRevenueNoncurrent
6652000
CY2021Q4 us-gaap Deferred Revenue Noncurrent
DeferredRevenueNoncurrent
0
CY2022Q3 us-gaap Deferred Compensation Liability Classified Noncurrent
DeferredCompensationLiabilityClassifiedNoncurrent
0
CY2021Q4 us-gaap Deferred Compensation Liability Classified Noncurrent
DeferredCompensationLiabilityClassifiedNoncurrent
2000
CY2022Q3 us-gaap Liabilities
Liabilities
33508000
CY2021Q4 us-gaap Liabilities
Liabilities
19071000
CY2022Q3 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.001
CY2021Q4 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.001
CY2022Q3 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
10000000
CY2021Q4 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
10000000
CY2022Q3 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0
CY2022Q3 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0
CY2021Q4 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0
CY2021Q4 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0
CY2022Q3 us-gaap Preferred Stock Value
PreferredStockValue
0
CY2021Q4 us-gaap Preferred Stock Value
PreferredStockValue
0
CY2022Q3 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2021Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2022Q3 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
200000000
CY2021Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
200000000
CY2022Q3 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
53796000
CY2022Q3 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
53796000
CY2021Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
47598000
CY2021Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
47597000
CY2022Q3 us-gaap Common Stocks Including Additional Paid In Capital
CommonStocksIncludingAdditionalPaidInCapital
750564000
CY2021Q4 us-gaap Common Stocks Including Additional Paid In Capital
CommonStocksIncludingAdditionalPaidInCapital
607581000
CY2022Q3 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
-5010000
CY2021Q4 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
-382000
CY2022Q3 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-394182000
CY2021Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-275255000
CY2022Q3 us-gaap Stockholders Equity
StockholdersEquity
351372000
CY2021Q4 us-gaap Stockholders Equity
StockholdersEquity
331944000
CY2022Q3 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
384880000
CY2021Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
351015000
CY2022Q3 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
458000
CY2021Q3 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
0
us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
4028000
us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
0
CY2022Q3 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
31987000
CY2021Q3 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
21580000
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
93234000
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
59651000
CY2022Q3 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
11925000
CY2021Q3 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
6227000
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
31120000
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
17163000
CY2022Q3 us-gaap Operating Expenses
OperatingExpenses
43912000
CY2021Q3 us-gaap Operating Expenses
OperatingExpenses
27807000
us-gaap Operating Expenses
OperatingExpenses
124354000
us-gaap Operating Expenses
OperatingExpenses
76814000
CY2022Q3 us-gaap Operating Income Loss
OperatingIncomeLoss
-43454000
CY2021Q3 us-gaap Operating Income Loss
OperatingIncomeLoss
-27807000
us-gaap Operating Income Loss
OperatingIncomeLoss
-120326000
us-gaap Operating Income Loss
OperatingIncomeLoss
-76814000
CY2022Q3 us-gaap Investment Income Interest
InvestmentIncomeInterest
1500000
CY2021Q3 us-gaap Investment Income Interest
InvestmentIncomeInterest
24000
us-gaap Investment Income Interest
InvestmentIncomeInterest
2413000
us-gaap Investment Income Interest
InvestmentIncomeInterest
77000
CY2022Q3 crnx Other Income Expense
OtherIncomeExpense
29000
CY2021Q3 crnx Other Income Expense
OtherIncomeExpense
-68000
crnx Other Income Expense
OtherIncomeExpense
-35000
crnx Other Income Expense
OtherIncomeExpense
-110000
CY2022Q3 crnx Change In Valuation Of Derivative Assets
ChangeInValuationOfDerivativeAssets
0
CY2021Q3 crnx Change In Valuation Of Derivative Assets
ChangeInValuationOfDerivativeAssets
0
crnx Change In Valuation Of Derivative Assets
ChangeInValuationOfDerivativeAssets
31000
crnx Change In Valuation Of Derivative Assets
ChangeInValuationOfDerivativeAssets
0
CY2022Q3 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
1529000
CY2021Q3 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
-44000
us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
2409000
us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
-33000
CY2022Q3 crnx Loss Before Equity Method Investment
LossBeforeEquityMethodInvestment
41925000
CY2021Q3 crnx Loss Before Equity Method Investment
LossBeforeEquityMethodInvestment
27851000
crnx Loss Before Equity Method Investment
LossBeforeEquityMethodInvestment
117917000
crnx Loss Before Equity Method Investment
LossBeforeEquityMethodInvestment
76847000
CY2022Q3 us-gaap Equity Method Investment Realized Gain Loss On Disposal
EquityMethodInvestmentRealizedGainLossOnDisposal
0
CY2021Q3 us-gaap Equity Method Investment Realized Gain Loss On Disposal
EquityMethodInvestmentRealizedGainLossOnDisposal
0
us-gaap Equity Method Investment Realized Gain Loss On Disposal
EquityMethodInvestmentRealizedGainLossOnDisposal
-1010000
us-gaap Equity Method Investment Realized Gain Loss On Disposal
EquityMethodInvestmentRealizedGainLossOnDisposal
0
CY2022Q3 us-gaap Net Income Loss
NetIncomeLoss
-41925000
CY2021Q3 us-gaap Net Income Loss
NetIncomeLoss
-27851000
us-gaap Net Income Loss
NetIncomeLoss
-118927000
us-gaap Net Income Loss
NetIncomeLoss
-76847000
CY2022Q3 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.78
CY2022Q3 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.78
CY2021Q3 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.73
CY2021Q3 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.73
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-2.32
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-2.32
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-2.13
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-2.13
CY2022Q3 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
53768000
CY2022Q3 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
53768000
CY2021Q3 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
38309000
CY2021Q3 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
38309000
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
51356000
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
51356000
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
36147000
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
36147000
CY2022Q3 us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
-1391000
CY2021Q3 us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
-22000
us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
-4628000
us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
-37000
CY2022Q3 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-43316000
CY2021Q3 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-27873000
us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-123555000
us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-76884000
CY2022Q2 us-gaap Stockholders Equity
StockholdersEquity
386165000
CY2022Q3 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
1089000
CY2022Q3 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
7434000
CY2022Q3 us-gaap Other Comprehensive Income Loss Net Of Tax
OtherComprehensiveIncomeLossNetOfTax
1391000
CY2022Q3 us-gaap Net Income Loss
NetIncomeLoss
-41925000
CY2022Q3 us-gaap Stockholders Equity
StockholdersEquity
351372000
CY2021Q4 us-gaap Stockholders Equity
StockholdersEquity
331944000
crnx Transaction Cost On Issuance Of Common Stock
TransactionCostOnIssuanceOfCommonStock
7800000
us-gaap Stock Issued During Period Value New Issues
StockIssuedDuringPeriodValueNewIssues
117242000
us-gaap Stock Issued During Period Value Employee Stock Purchase Plan
StockIssuedDuringPeriodValueEmployeeStockPurchasePlan
813000
crnx Vesting Of Shares Of Common Stock Value Subject To Repurchase
VestingOfSharesOfCommonStockValueSubjectToRepurchase
2000
us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
4606000
us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
20320000
us-gaap Other Comprehensive Income Loss Net Of Tax
OtherComprehensiveIncomeLossNetOfTax
4628000
us-gaap Net Income Loss
NetIncomeLoss
-118927000
CY2022Q3 us-gaap Stockholders Equity
StockholdersEquity
351372000
CY2021Q2 us-gaap Stockholders Equity
StockholdersEquity
201440000
CY2021Q3 crnx Transaction Cost On Issuance Of Common Stock
TransactionCostOnIssuanceOfCommonStock
24000000
CY2021Q3 us-gaap Stock Issued During Period Value New Issues
StockIssuedDuringPeriodValueNewIssues
14976000
CY2021Q3 crnx Vesting Of Shares Of Common Stock Value Subject To Repurchase
VestingOfSharesOfCommonStockValueSubjectToRepurchase
5000
CY2021Q3 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
487000
CY2021Q3 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
4555000
CY2021Q3 us-gaap Other Comprehensive Income Loss Net Of Tax
OtherComprehensiveIncomeLossNetOfTax
22000
CY2021Q3 us-gaap Net Income Loss
NetIncomeLoss
-27851000
CY2021Q3 us-gaap Stockholders Equity
StockholdersEquity
193590000
CY2020Q4 us-gaap Stockholders Equity
StockholdersEquity
168919000
crnx Transaction Cost On Issuance Of Common Stock
TransactionCostOnIssuanceOfCommonStock
2400000
us-gaap Stock Issued During Period Value New Issues
StockIssuedDuringPeriodValueNewIssues
87534000
us-gaap Stock Issued During Period Value Employee Stock Purchase Plan
StockIssuedDuringPeriodValueEmployeeStockPurchasePlan
522000
crnx Vesting Of Shares Of Common Stock Value Subject To Repurchase
VestingOfSharesOfCommonStockValueSubjectToRepurchase
16000
us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
1289000
us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
12194000
us-gaap Other Comprehensive Income Loss Net Of Tax
OtherComprehensiveIncomeLossNetOfTax
37000
us-gaap Net Income Loss
NetIncomeLoss
-76847000
CY2021Q3 us-gaap Stockholders Equity
StockholdersEquity
193590000
us-gaap Net Income Loss
NetIncomeLoss
-118927000
us-gaap Net Income Loss
NetIncomeLoss
-76847000
us-gaap Share Based Compensation
ShareBasedCompensation
20320000
us-gaap Share Based Compensation
ShareBasedCompensation
12194000
us-gaap Depreciation And Amortization
DepreciationAndAmortization
703000
us-gaap Depreciation And Amortization
DepreciationAndAmortization
687000
crnx Non Cash Lease Expense
NonCashLeaseExpense
298000
crnx Non Cash Lease Expense
NonCashLeaseExpense
249000
us-gaap Accretion Amortization Of Discounts And Premiums Investments
AccretionAmortizationOfDiscountsAndPremiumsInvestments
-385000
us-gaap Accretion Amortization Of Discounts And Premiums Investments
AccretionAmortizationOfDiscountsAndPremiumsInvestments
-236000
us-gaap Equity Method Investment Realized Gain Loss On Disposal
EquityMethodInvestmentRealizedGainLossOnDisposal
-1010000
us-gaap Equity Method Investment Realized Gain Loss On Disposal
EquityMethodInvestmentRealizedGainLossOnDisposal
0
crnx Change In Valuation Of Derivative Assets
ChangeInValuationOfDerivativeAssets
31000
crnx Change In Valuation Of Derivative Assets
ChangeInValuationOfDerivativeAssets
0
us-gaap Other Noncash Income Expense
OtherNoncashIncomeExpense
0
us-gaap Other Noncash Income Expense
OtherNoncashIncomeExpense
-8000
us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
-1052000
us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
3996000
us-gaap Increase Decrease In Accounts Payable And Accrued Liabilities
IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
6911000
us-gaap Increase Decrease In Accounts Payable And Accrued Liabilities
IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
2395000
us-gaap Increase Decrease In Commodity Contract Assets And Liabilities
IncreaseDecreaseInCommodityContractAssetsAndLiabilities
-8972000
us-gaap Increase Decrease In Commodity Contract Assets And Liabilities
IncreaseDecreaseInCommodityContractAssetsAndLiabilities
0
crnx Increase Decrease In Operating Lease Liabilities
IncreaseDecreaseInOperatingLeaseLiabilities
-691000
crnx Increase Decrease In Operating Lease Liabilities
IncreaseDecreaseInOperatingLeaseLiabilities
-615000
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-79998000
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-65689000
us-gaap Payments To Acquire Available For Sale Securities Debt
PaymentsToAcquireAvailableForSaleSecuritiesDebt
296256000
us-gaap Payments To Acquire Available For Sale Securities Debt
PaymentsToAcquireAvailableForSaleSecuritiesDebt
23380000
us-gaap Proceeds From Sale And Maturity Of Available For Sale Securities
ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities
86805000
us-gaap Proceeds From Sale And Maturity Of Available For Sale Securities
ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities
69113000
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
1382000
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
418000
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-210833000
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
45315000
us-gaap Sale Of Stock Consideration Received On Transaction
SaleOfStockConsiderationReceivedOnTransaction
7800000
us-gaap Sale Of Stock Consideration Received On Transaction
SaleOfStockConsiderationReceivedOnTransaction
2400000
us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
117242000
us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
87534000
us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
4606000
us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
1289000
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
121848000
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
88823000
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
-168983000
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
68449000
CY2021Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
201195000
CY2020Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
93587000
CY2022Q3 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
32212000
CY2021Q3 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
162036000
CY2022Q3 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
30912000
CY2021Q3 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
161536000
CY2022Q3 us-gaap Restricted Cash
RestrictedCash
1300000
CY2021Q3 us-gaap Restricted Cash
RestrictedCash
500000
CY2022Q3 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
32212000
CY2021Q3 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
162036000
crnx Change In Unvested Stock Liability
ChangeInUnvestedStockLiability
2000
crnx Change In Unvested Stock Liability
ChangeInUnvestedStockLiability
16000
crnx Purchase Of Shares Pursuant To Employee Stock Purchase Plan
PurchaseOfSharesPursuantToEmployeeStockPurchasePlan
813000
crnx Purchase Of Shares Pursuant To Employee Stock Purchase Plan
PurchaseOfSharesPursuantToEmployeeStockPurchasePlan
522000
us-gaap Capital Expenditures Incurred But Not Yet Paid
CapitalExpendituresIncurredButNotYetPaid
60000
us-gaap Capital Expenditures Incurred But Not Yet Paid
CapitalExpendituresIncurredButNotYetPaid
0
us-gaap Number Of Operating Segments
NumberOfOperatingSegments
1
CY2022Q3 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-394200000
CY2022Q3 us-gaap Cash Cash Equivalents And Short Term Investments
CashCashEquivalentsAndShortTermInvestments
368400000
us-gaap Use Of Estimates
UseOfEstimates
<p style="text-indent:0.0%;font-size:10.0pt;margin-top:4.5pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Use of Estimates</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:9.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The Company’s condensed consolidated financial statements are prepared in accordance with GAAP. The preparation of the Company’s condensed consolidated financial statements requires it to make estimates and assumptions that impact the reported amounts of assets, liabilities, revenues and expenses and the disclosure of contingent assets and liabilities in the Company’s condensed consolidated financial statements and accompanying notes. The most significant estimates in the Company’s condensed consolidated financial statements relate to accrual of research and development expenses, valuation of stock-based awards, fair values of financial instruments, revenue recognition and equity method investment. </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Although these estimates are based on the Company’s knowledge of current events and actions it may undertake in the future, actual results may ultimately materially differ from these estimates and assumptions.</span></p>
us-gaap Concentration Risk Credit Risk
ConcentrationRiskCreditRisk
<p style="text-indent:0.0%;font-size:10.0pt;margin-top:9.0pt;line-height:1.1020833333333333;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Concentrations of Credit Risk</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:4.5pt;line-height:1.1020833333333333;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Financial instruments that potentially subject the Company to significant concentrations of credit risk consist primarily of cash, cash equivalents and investment securities. The Company maintains deposits in federally insured financial institutions in excess of federally insured limits. The Company has not experienced any losses in such accounts and believes it is not exposed to significant risk on its cash balances due to the financial position of the depository institution in which those deposits are held. Additionally, the Company has established guidelines regarding approved investments and maturities of investments, which are designed to maintain safety and liquidity.</span></p>
CY2022Q3 crnx Tax Incentive Receivable Reduction In Research And Development Expense
TaxIncentiveReceivableReductionInResearchAndDevelopmentExpense
300000
crnx Tax Incentive Receivable Reduction In Research And Development Expense
TaxIncentiveReceivableReductionInResearchAndDevelopmentExpense
700000
CY2021Q3 crnx Tax Incentive Receivable Reduction In Research And Development Expense
TaxIncentiveReceivableReductionInResearchAndDevelopmentExpense
100000
crnx Tax Incentive Receivable Reduction In Research And Development Expense
TaxIncentiveReceivableReductionInResearchAndDevelopmentExpense
300000
us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
9177000
us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
6611000
CY2022Q3 us-gaap Available For Sale Debt Securities Amortized Cost Basis
AvailableForSaleDebtSecuritiesAmortizedCostBasis
342460000
CY2022Q3 us-gaap Available For Sale Debt Securities Accumulated Gross Unrealized Gain Before Tax
AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
20000
CY2022Q3 us-gaap Available For Sale Debt Securities Accumulated Gross Unrealized Loss Before Tax
AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
5030000
CY2022Q3 us-gaap Available For Sale Securities Debt Securities
AvailableForSaleSecuritiesDebtSecurities
337450000
CY2021Q4 us-gaap Available For Sale Debt Securities Amortized Cost Basis
AvailableForSaleDebtSecuritiesAmortizedCostBasis
133393000
CY2021Q4 us-gaap Available For Sale Debt Securities Accumulated Gross Unrealized Gain Before Tax
AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
7000
CY2021Q4 us-gaap Available For Sale Debt Securities Accumulated Gross Unrealized Loss Before Tax
AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
388000
CY2021Q4 us-gaap Available For Sale Securities Debt Securities
AvailableForSaleSecuritiesDebtSecurities
133012000
CY2022Q3 us-gaap Available For Sale Securities Debt Maturities Within One Year Amortized Cost
AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost
253769000
CY2022Q3 us-gaap Available For Sale Securities Debt Maturities Within One Year Fair Value
AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue
250971000
CY2021Q4 us-gaap Available For Sale Securities Debt Maturities Within One Year Amortized Cost
AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost
31101000
CY2021Q4 us-gaap Available For Sale Securities Debt Maturities Within One Year Fair Value
AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue
31078000
CY2022Q3 us-gaap Available For Sale Securities Debt Maturities After One Through Five Years Amortized Cost
AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsAmortizedCost
88691000
CY2022Q3 us-gaap Available For Sale Securities Debt Maturities After One Through Five Years Fair Value
AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue
86479000
CY2021Q4 us-gaap Available For Sale Securities Debt Maturities After One Through Five Years Amortized Cost
AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsAmortizedCost
102292000
CY2021Q4 us-gaap Available For Sale Securities Debt Maturities After One Through Five Years Fair Value
AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue
101934000
CY2022Q3 us-gaap Available For Sale Securities Debt Maturities Single Maturity Date Amortized Cost Basis
AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDateAmortizedCostBasis
342460000
CY2022Q3 us-gaap Available For Sale Securities Debt Maturities Single Maturity Date
AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDate
337450000
CY2021Q4 us-gaap Available For Sale Securities Debt Maturities Single Maturity Date Amortized Cost Basis
AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDateAmortizedCostBasis
133393000
CY2021Q4 us-gaap Available For Sale Securities Debt Maturities Single Maturity Date
AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDate
133012000
CY2022Q3 us-gaap Debt Securities Available For Sale Continuous Unrealized Loss Position12 Months Or Longer Number Of Positions
DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerNumberOfPositions
0
CY2021Q4 us-gaap Debt Securities Available For Sale Continuous Unrealized Loss Position12 Months Or Longer Number Of Positions
DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerNumberOfPositions
0
crnx Change In Valuation Of Derivative Asset
ChangeInValuationOfDerivativeAsset
31000
us-gaap Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Asset Transfers Out Of Level3
FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersOutOfLevel3
0
CY2021 us-gaap Fair Value Measurement With Unobservable Inputs Reconciliation Liability Transfers Out Of Level3
FairValueMeasurementWithUnobservableInputsReconciliationLiabilityTransfersOutOfLevel3
0
CY2022Q3 crnx Prepaid Research And Development Costs Current
PrepaidResearchAndDevelopmentCostsCurrent
4636000
CY2021Q4 crnx Prepaid Research And Development Costs Current
PrepaidResearchAndDevelopmentCostsCurrent
7184000
CY2022Q3 crnx Foreign Tax Incentive Receivable Current
ForeignTaxIncentiveReceivableCurrent
852000
CY2021Q4 crnx Foreign Tax Incentive Receivable Current
ForeignTaxIncentiveReceivableCurrent
977000
CY2022Q3 us-gaap Prepaid Insurance
PrepaidInsurance
1328000
CY2021Q4 us-gaap Prepaid Insurance
PrepaidInsurance
888000
CY2022Q3 us-gaap Interest Receivable Current
InterestReceivableCurrent
1401000
CY2021Q4 us-gaap Interest Receivable Current
InterestReceivableCurrent
499000
CY2022Q3 us-gaap Due From Affiliate Current
DueFromAffiliateCurrent
92000
CY2021Q4 us-gaap Due From Affiliate Current
DueFromAffiliateCurrent
553000
CY2022Q3 us-gaap Other Assets Current
OtherAssetsCurrent
1652000
CY2021Q4 us-gaap Other Assets Current
OtherAssetsCurrent
912000
CY2022Q3 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
9961000
CY2021Q4 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
11013000
CY2022Q3 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
7370000
CY2021Q4 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
6305000
CY2022Q3 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
3806000
CY2021Q4 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
3480000
CY2022Q3 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
3564000
CY2021Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
2825000
us-gaap Operating Lease Payments
OperatingLeasePayments
900000
CY2021Q3 us-gaap Operating Lease Payments
OperatingLeasePayments
900000
CY2022Q3 us-gaap Accounts Payable Current
AccountsPayableCurrent
5877000
CY2021Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
3422000
CY2022Q3 crnx Accrued Outside Services And Professional Fees
AccruedOutsideServicesAndProfessionalFees
1783000
CY2021Q4 crnx Accrued Outside Services And Professional Fees
AccruedOutsideServicesAndProfessionalFees
537000
CY2022Q3 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
433000
CY2021Q4 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
323000
CY2022Q3 crnx Accrued Research And Development Costs
AccruedResearchAndDevelopmentCosts
5402000
CY2021Q4 crnx Accrued Research And Development Costs
AccruedResearchAndDevelopmentCosts
4186000
CY2022Q3 us-gaap Accounts Payable And Accrued Liabilities Current
AccountsPayableAndAccruedLiabilitiesCurrent
13495000
CY2021Q4 us-gaap Accounts Payable And Accrued Liabilities Current
AccountsPayableAndAccruedLiabilitiesCurrent
8468000
CY2022Q3 us-gaap Lessee Operating Lease Liability Payments Remainder Of Fiscal Year
LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear
308000
CY2022Q3 us-gaap Lessee Operating Lease Liability Payments Due Next Twelve Months
LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths
1244000
CY2022Q3 us-gaap Lessee Operating Lease Liability Payments Due Year Two
LesseeOperatingLeaseLiabilityPaymentsDueYearTwo
1280000
CY2022Q3 us-gaap Lessee Operating Lease Liability Payments Due Year Three
LesseeOperatingLeaseLiabilityPaymentsDueYearThree
871000
CY2022Q3 us-gaap Lessee Operating Lease Liability Payments Due
LesseeOperatingLeaseLiabilityPaymentsDue
3703000
CY2022Q3 us-gaap Lessee Operating Lease Liability Undiscounted Excess Amount
LesseeOperatingLeaseLiabilityUndiscountedExcessAmount
381000
CY2022Q3 us-gaap Operating Lease Liability
OperatingLeaseLiability
3322000
CY2022Q3 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
1022000
CY2022Q3 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
2300000
CY2022Q3 us-gaap Operating Leases Rent Expense Net
OperatingLeasesRentExpenseNet
300000
us-gaap Operating Leases Rent Expense Net
OperatingLeasesRentExpenseNet
900000
CY2021Q3 us-gaap Operating Leases Rent Expense Net
OperatingLeasesRentExpenseNet
300000
us-gaap Operating Leases Rent Expense Net
OperatingLeasesRentExpenseNet
900000
CY2022Q3 us-gaap Operating Lease Weighted Average Remaining Lease Term1
OperatingLeaseWeightedAverageRemainingLeaseTerm1
P2Y9M18D
CY2021Q4 us-gaap Operating Lease Weighted Average Remaining Lease Term1
OperatingLeaseWeightedAverageRemainingLeaseTerm1
P3Y7M6D
CY2022Q3 us-gaap Operating Lease Payments
OperatingLeasePayments
300000
us-gaap Operating Lease Payments
OperatingLeasePayments
300000
CY2022Q3 crnx Upfront Payment As License Revenue
UpfrontPaymentAsLicenseRevenue
500000
crnx Upfront Payment As License Revenue
UpfrontPaymentAsLicenseRevenue
4000000.0
CY2022Q3 us-gaap Deferred Revenue
DeferredRevenue
2300000
CY2022Q3 us-gaap Deferred Revenue Noncurrent
DeferredRevenueNoncurrent
6700000
CY2019Q3 crnx Maximum Amount Of Common Stock Preferred Stock Debt Securities Warrants And Units To Be Issued
MaximumAmountOfCommonStockPreferredStockDebtSecuritiesWarrantsAndUnitsToBeIssued
300000000.0
dei Document Effective Date
DocumentEffectiveDate
2019-08-29
CY2019Q3 us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
75000000.0
CY2021Q3 crnx Maximum Share Of Common Stock Preferred Stock Debt Securities Warrants And Units To Be Issued
MaximumShareOfCommonStockPreferredStockDebtSecuritiesWarrantsAndUnitsToBeIssued
851306
CY2022Q3 us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
150000000
CY2021Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
6553594
CY2021Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
16.07
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
3035404
us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
20.40
us-gaap Stock Issued During Period Shares Stock Options Exercised
StockIssuedDuringPeriodSharesStockOptionsExercised
506646
us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
9.09
crnx Share Based Compensation Arrangement By Share Based Payment Award Options Forfeited And Expired
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeitedAndExpired
183315
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures And Expirations In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice
19.09
CY2022Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
8899037
CY2022Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
17.89
us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
P8Y1M6D
CY2022Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
27757000
CY2022Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber
8899037
CY2022Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice
17.89
us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested And Expected To Vest Outstanding Weighted Average Remaining Contractual Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1
P8Y1M6D
CY2022Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Aggregate Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue
27757000
CY2022Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber
3764679
CY2022Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice
15.45
us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Weighted Average Remaining Contractual Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1
P6Y10M24D
CY2022Q3 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Intrinsic Value1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1
21287000
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercises In Period Total Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue
5600000
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
0
CY2022Q3 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
7434000
CY2021Q3 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
4555000
us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
20320000
us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
12194000

Files In Submission

Name View Source Status
crnx-20220930_cal.xml Edgar Link unprocessable
0000950170-22-024736-index-headers.html Edgar Link pending
0000950170-22-024736-index.html Edgar Link pending
0000950170-22-024736.txt Edgar Link pending
0000950170-22-024736-xbrl.zip Edgar Link pending
crnx-20220930.htm Edgar Link pending
crnx-20220930.xsd Edgar Link pending
crnx-ex10_1.htm Edgar Link pending
crnx-ex10_2.htm Edgar Link pending
crnx-ex10_3.htm Edgar Link pending
crnx-ex31_1.htm Edgar Link pending
crnx-ex31_2.htm Edgar Link pending
crnx-ex32_1.htm Edgar Link pending
Financial_Report.xlsx Edgar Link pending
img194730251_0.jpg Edgar Link pending
img194730251_1.jpg Edgar Link pending
img194730251_2.jpg Edgar Link pending
img194730251_3.jpg Edgar Link pending
img194730251_4.jpg Edgar Link pending
img194730251_5.jpg Edgar Link pending
img194730251_6.jpg Edgar Link pending
img194730251_7.jpg Edgar Link pending
img194730251_8.jpg Edgar Link pending
MetaLinks.json Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
crnx-20220930_lab.xml Edgar Link unprocessable
crnx-20220930_pre.xml Edgar Link unprocessable
crnx-20220930_def.xml Edgar Link unprocessable
crnx-20220930_htm.xml Edgar Link completed
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R35.htm Edgar Link pending
R36.htm Edgar Link pending
R37.htm Edgar Link pending
R38.htm Edgar Link pending
R39.htm Edgar Link pending
R4.htm Edgar Link pending
R40.htm Edgar Link pending
R41.htm Edgar Link pending
R42.htm Edgar Link pending
R43.htm Edgar Link pending
R44.htm Edgar Link pending
R5.htm Edgar Link pending
R6.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending
FilingSummary.xml Edgar Link unprocessable